Stemline Therapeutics announces upsizing and pricing of $80 million public offering
Stemline Therapeutics announced the pricing of an underwritten public offering of 8,888,889 shares of its common stock at a price of $9.00 per share, with expected gross proceeds to Stemline of $80 million. Due to demand, this offering was upsized from the previously announced 6,600,000 shares. January 15, 2019